SAN DIEGO, Oct. 5, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2023 following the close of market on Thursday, November 9, 2023.
On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Conference Call Details
The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, November 9, 2023. Interested parties may access the live teleconference through the Investor Info section of Illumina's website at investor.illumina.com. Alternatively, individuals can access the call by dialing 866.400.0049 or +1.323.794.2149 outside North America, both with Conference ID 1991305. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.
A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023, we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, TikTok and YouTube.
Investors: | |
Salli Schwartz | |
+1.858.291.6421 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. | |
Media: | |
David McAlpine | |
+1.347.327.1336 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$99.97 |
| Daily Change: | 2.74 2.82 |
| Daily Volume: | 1,202,205 |
| Market Cap: | US$15.370B |
October 15, 2025 September 23, 2025 September 03, 2025 August 19, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
